Can tirzepatide (Mounjaro) cause increased bruising?

Increased Bruising with Mounjaro (Tirzepatide)

Increased bruising is not a commonly reported or established adverse effect of Mounjaro (tirzepatide) based on current clinical evidence. The FDA prescribing information and major clinical trials do not list bruising as a significant adverse reaction 1.

What the Evidence Shows

Common Side Effects of Tirzepatide

The most frequently reported adverse effects of tirzepatide are gastrointestinal in nature, occurring primarily during dose escalation 2, 3:

• Nausea (10-31% depending on dose)
• Diarrhea (7-23%)
• Vomiting (2-12%)
• Constipation (3-7%)
• Abdominal pain (3-6%)

Documented Skin-Related Reactions

The FDA label and clinical trials document specific dermatologic adverse events 1:

• Injection site reactions (3.2% vs 0.4% placebo) - including pain, redness, or swelling at injection sites
• Hypersensitivity reactions (3.2% vs 1.7% placebo) - including urticaria and eczema
• Alopecia (6% at highest dose)

What About Bruising?

Bruising is not listed among the adverse reactions in the FDA prescribing information for tirzepatide 1. The comprehensive safety data from the SURMOUNT and SURPASS trials, which included thousands of patients, do not identify bruising as a notable adverse effect 3.

Important Clinical Considerations

If a Patient Reports Increased Bruising on Tirzepatide:

1. Evaluate other causes first:

   • Review all medications (antiplatelet agents, anticoagulants, NSAIDs, supplements)
   • Check for underlying coagulopathy or platelet disorders
   • Assess for trauma or mechanical causes at injection sites
   • Consider nutritional deficiencies (vitamin C, vitamin K)

2. Injection technique matters:

   • Proper subcutaneous injection technique minimizes local trauma
   • Rotating injection sites (abdomen, thigh, upper arm) reduces repeated trauma 1
   • Using appropriate needle size and avoiding blood vessels

3. Monitor for serious conditions:

   • If bruising is extensive, spontaneous, or accompanied by other bleeding symptoms, evaluate for thrombocytopenia or coagulation disorders
   • This would not be a typical tirzepatide effect but warrants investigation

Key Safety Monitoring

While bruising is not a concern, patients on tirzepatide should be monitored for 3:

• Gastrointestinal symptoms (most common)
• Gallbladder disease (increased risk with all GLP-1 receptor agonists)
• Pancreatitis (rare but serious)
• Hypoglycemia (when combined with insulin or sulfonylureas)
• Heart rate increases (2-4 beats per minute average)

In summary, if a patient on Mounjaro reports increased bruising, look for alternative explanations rather than attributing it to the medication itself, as this is not a recognized adverse effect of tirzepatide.